Tourmaline Bio, Inc. (TRML)
47.98
0.00 (0.00%)
USD |
NASDAQ |
Dec 11, 16:00
Tourmaline Bio Cash from Investing (Quarterly): 16.30M for June 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Novartis AG | -858.23M |
| Merck & Co., Inc. | -283.00M |
| UnitedHealth Group, Inc. | -4.558B |
| Gilead Sciences, Inc. | -427.00M |
| Eli Lilly & Co. | -2.983B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.26M |
| Cash from Financing (Quarterly) | 0.054M |
| Free Cash Flow | -86.30M |
| Free Cash Flow Per Share (Quarterly) | -0.7871 |
| Free Cash Flow to Equity (Quarterly) | -20.22M |
| Free Cash Flow to Firm (Quarterly) | -20.27M |
| Free Cash Flow Yield | -6.98% |